SCHEMBL22290905

SCHEMBL22290905

CC(=O)n1ccc(C(=O)O)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.40
TP53 P04637 1/20 0.40
ALDH1A1 P00352 7/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
DAO P14920 1/20 0.37
NAPRT Q6XQN6 1/20 0.37
HPGDS O60760 1/20 0.36
ALKBH2 Q6NS38 1/20 0.36
PKM P14618 1/20 0.36
SRD5A2 P31213 2/20 0.36
POLB P06746 3/20 0.35
TDP1 Q9NUW8 3/20 0.35
KDM4E B2RXH2 3/20 0.35
MEN1 O00255 2/20 0.35
MAPT P10636 2/20 0.35
KMT2A Q03164 2/20 0.35
HPGD P15428 2/20 0.35
APEX1 P27695 1/20 0.35
NR4A1 P22736 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9309968 0.82 TSHR (0.43) TSHRTP53ALDH1A1SMN1; SMN2DAO
SCHEMBL3543689 0.78 TSHR (0.40) TSHRTP53ALDH1A1SMN1; SMN2DAO
SCHEMBL4900653 0.78 BCHE (0.36) TSHRTP53ALDH1A1SMN1; SMN2DAO
SCHEMBL27814139 0.78 MAPT (0.40) TSHRTP53ALDH1A1SMN1; SMN2MEN1
SCHEMBL21408507 0.74 MAOA (0.38) TSHRTP53ALDH1A1DAONAPRT
SCHEMBL19638080 0.74 GPR119 (0.38) TSHRALDH1A1PKMSRD5A2TDP1
SCHEMBL369526 0.73
SCHEMBL6627411 0.73
SCHEMBL29218330 0.71
SCHEMBL28809782 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3917527-B1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC (US) 2025-04-23 EP disclosed
CN-113645971-B Compounds and uses thereof 福宏治疗公司 2024-10-18 CN disclosed
US-20230079819-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-03-16 US disclosed
CN-111868026-B Capsid protein assembly inhibitor containing N-heterocyclic five-membered ring, pharmaceutical composition and application thereof 正大天晴药业集团股份有限公司 2022-11-25 CN disclosed
EP-3917527-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2021-12-08 EP disclosed
CN-113645971-A Compound and use thereof 福宏治疗公司 2021-11-12 CN disclosed
WO-2020160180-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2020-08-06 WO disclosed
WO-2020160180-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2020-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079819-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB TSHR 4351/4885TP53 908/4885ALDH1A1 2571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.